Ultragenyx Pharmaceutical (RARE): Reassessing Valuation After Recent Share Price Rebound [Yahoo! Finance]
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: Yahoo! Finance
See our latest analysis for Ultragenyx Pharmaceutical. That recent 30 day share price return of around 9.5 percent, on top of a roughly 25 percent gain over 90 days, suggests momentum is rebuilding even though the one year total shareholder return is still deeply negative. If Ultragenyx's rebound has caught your eye, it may be a good moment to scan other innovative names across healthcare and biotech using healthcare stocks With revenue growing fast but losses still heavy and the share price far below analyst targets, investors face a familiar dilemma: is Ultragenyx a mispriced rare disease leader, or is the market already factoring in its future growth? With Ultragenyx shares last closing at $36.23 versus a narrative fair value of $81.85, the valuation story leans heavily toward long term upside potential. Ultragenyx's clinical pipeline is advancing with five Phase III programs (including UX143 and GTX-102), multiple BLA submissions expected in the coming quarters, and nea
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? [Yahoo! Finance]Yahoo! Finance
- Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest [Yahoo! Finance]Yahoo! Finance
- Ultragenyx to Participate in Investor Conferences in DecemberGlobeNewswire
- Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Barclays PLC from $81.00 to $50.00. They now have an "overweight" rating on the stock.MarketBeat
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
RARE
Earnings
- 11/4/25 - Miss
RARE
Sec Filings
- 12/11/25 - Form 4
- 12/10/25 - Form 144
- 11/5/25 - Form SCHEDULE
- RARE's page on the SEC website